Superworth

Agios Pharmaceuticals price to book ratio AGIO

Market value divided by the book value of the company's net assets, since 2013.

Today, Oct 23, 2026
2.2×
10-year median
2.3×
Against its 10-year history
49th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.8× to 13.3×
Peer median
3.2×

Agios Pharmaceuticals' price to book ratio is 2.2× as of Oct 23, 2026.

That is below its ten-year median of 2.3×, close to the middle of its last ten years.

Over that time it ranged from 0.8× in Jun 2022 to 13.3× in Apr 2018.

The median for 10 large drugmakers of a similar size is 3.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.2×1.2×2.2×
20251.3×1.0×2.0×
20241.2×1.2×4.0×
20231.4×1.1×1.6×
20221.5×0.8×1.7×
20211.3×1.2×9.5×
20206.2×3.6×7.0×
20196.4×3.6×6.4×
20183.5×3.3×13.3×
20176.2×4.3×9.6×
20164.4×3.8×7.0×
20156.5×5.4×22.1×
201419.1×5.0×20.0×
20135.4×3.8×5.4×

Against its peers

Companies in Drug Manufacturers - General nearest Agios Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
AGIOAgios Pharmaceuticals2.2×
PBHPrestige Consumer Healthcare1.2×
HRMYHarmony Biosciences2.1×
NRIXNurix Therapeutics2.9×
ANIPANI Pharmaceuticals2.8×
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
PCRXPacira BioSciences2.2×
OGNOrganon3.6×
LQDALiquidia19.6×
ARQTArcutis Biotherapeutics17.8×
Peer median3.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Agios Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.